BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28521285)

  • 1. ARID1B alterations identify aggressive tumors in neuroblastoma.
    Lee SH; Kim JS; Zheng S; Huse JT; Bae JS; Lee JW; Yoo KH; Koo HH; Kyung S; Park WY; Sung KW
    Oncotarget; 2017 Jul; 8(28):45943-45950. PubMed ID: 28521285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
    Sausen M; Leary RJ; Jones S; Wu J; Reynolds CP; Liu X; Blackford A; Parmigiani G; Diaz LA; Papadopoulos N; Vogelstein B; Kinzler KW; Velculescu VE; Hogarty MD
    Nat Genet; 2013 Jan; 45(1):12-7. PubMed ID: 23202128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIAM1 variants improve clinical outcome in neuroblastoma.
    Sanmartín E; Yáñez Y; Fornés-Ferrer V; Zugaza JL; Cañete A; Castel V; Font de Mora J
    Oncotarget; 2017 Jul; 8(28):45286-45297. PubMed ID: 28423360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between ARID1B gene mutation (p.A460, p.V215G) and prognosis of high-risk refractory neuroblastoma.
    Zhang Y; Chen M; Huang D; Gu H; Yi Y; Meng X
    Cell Biol Int; 2023 Jul; 47(7):1222-1228. PubMed ID: 36883912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
    Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
    Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
    Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
    Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
    Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
    Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic mutations of ALK kinase in neuroblastoma.
    Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
    Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
    Wang K; Diskin SJ; Zhang H; Attiyeh EF; Winter C; Hou C; Schnepp RW; Diamond M; Bosse K; Mayes PA; Glessner J; Kim C; Frackelton E; Garris M; Wang Q; Glaberson W; Chiavacci R; Nguyen L; Jagannathan J; Saeki N; Sasaki H; Grant SF; Iolascon A; Mosse YP; Cole KA; Li H; Devoto M; McGrady PW; London WB; Capasso M; Rahman N; Hakonarson H; Maris JM
    Nature; 2011 Jan; 469(7329):216-20. PubMed ID: 21124317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Alterations Detected by Targeted Next-generation Sequencing and Their Clinical Implications in Neuroblastoma.
    Koh KN; Lee JY; Lim J; Shin J; Kang SH; Suh JK; Kim H; Im HJ; Namgoong JM; Kim DY; Jang SJ; Chun SM
    Anticancer Res; 2020 Dec; 40(12):7057-7065. PubMed ID: 33288603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
    Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
    Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma.
    Bellini A; Bessoltane-Bentahar N; Bhalshankar J; Clement N; Raynal V; Baulande S; Bernard V; Danzon A; Chicard M; Colmet-Daage L; Pierron G; Le Roux L; Planchon JM; Combaret V; Lapouble E; Corradini N; Thebaud E; Gambart M; Valteau-Couanet D; Michon J; Louis-Brennetot C; Janoueix-Lerosey I; Defachelles AS; Bourdeaut F; Delattre O; Schleiermacher G
    Int J Cancer; 2019 Nov; 145(10):2781-2791. PubMed ID: 31018240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression.
    Morales La Madrid A; Nall MB; Ouyang K; Minor A; Raca G; Kent P; Miller I; Schleiermacher G; Janoueix-Lerosey I; Cohn SL
    Pediatr Blood Cancer; 2013 Feb; 60(2):332-5. PubMed ID: 22997192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
    Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
    Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using droplet digital PCR to analyze
    Lodrini M; Sprüssel A; Astrahantseff K; Tiburtius D; Konschak R; Lode HN; Fischer M; Keilholz U; Eggert A; Deubzer HE
    Oncotarget; 2017 Oct; 8(49):85234-85251. PubMed ID: 29156716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.